Compare · DFTX vs HPCO
DFTX vs HPCO
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Hempacco Co. Inc. (HPCO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and HPCO operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX carries a market cap of $4.60B.
- DFTX has hit the wire 8 times in the past 4 weeks while HPCO has been quiet.
- DFTX has more recent analyst coverage (8 ratings vs 0 for HPCO).
- Company
- Definium Therapeutics Inc.
- Hempacco Co. Inc.
- Price
- $32.12-6.23%
- $0.62-11.65%
- Market cap
- $4.60B
- -
- 1M return
- -17.01%
- -
- 1Y return
- +144.26%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- News (4w)
- 8
- 0
- Recent ratings
- 8
- 0
Latest DFTX
- Definium Therapeutics Announces New Employee Inducement Grants
- Analyst initiated coverage on Definium Therapeutics with a new price target
- Chief Medical Officer Karlin Daniel sold $396,894 worth of shares (10,853 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 792,846 units (SEC Form 4) (withholding obligation)
- Chief Executive Officer Barrow Robert sold $1,153,784 worth of shares (31,550 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 2,213,090 units (SEC Form 4) (for withholding tax)
- Chief Commercial Officer Wiley Matthew T. sold $113,257 worth of shares (3,097 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.86% to 359,036 units (SEC Form 4) (for tax liability)
- Chief Legal Officer Sullivan Mark sold $513,845 worth of shares (14,051 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 494,228 units (SEC Form 4) to satisfy withholding tax
- Chief Financial Officer Roberts Brandi sold $123,497 worth of shares (3,377 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.85% to 394,528 units (SEC Form 4) (withholding tax)
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form 144 filed by Definium Therapeutics Inc.
- SEC Form 144 filed by Definium Therapeutics Inc.
Latest HPCO
- Hempacco Co. Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Hempacco Co. Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Hempacco Co. Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Hempacco Co. Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Unregistered Sales of Equity Securities
- SEC Form NT 10-Q filed by Hempacco Co. Inc.
- SEC Form DEFA14A filed by Hempacco Co. Inc.
- SEC Form DEF 14A filed by Hempacco Co. Inc.
- Hempacco Co. Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SEC Form 10-K filed by Hempacco Co. Inc.
- Hempacco Co. Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing